子宫腺肌病患者采用曼月乐联合小剂量米非司酮治疗的效果及对血清神经生长因子可溶性CD147血管内皮生长因子水平变化的影响

doi:10.3969/j.issn.1006-6233.2019.01.013

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (1209 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To discuss the clinical efficacy of menorrine combined with small dose mifepristone in treatment adenomyosis patients and its influences on nerve growth factor (NGF), soluble CD147 (sCD147), vascular endothelial growth factor (VEGF) . Methods: 92 patients with adenomyosis who received therapy from April 2015 to April 2017 in our hospital were treated, according to simple random number table method, those patients were divided into control group and the research group, with 46 cases in each group. The control group was treated with mirena, and the research group was treated with low-dose mifepristone based on the control group. Then clinical outcomes, menstrual volume, menstrual pain score, endometrial thickness, uterine volume, serum NGF, sCD147, VEGF before treatment, 2 months, 4 months after treatment, and adverse reactions occurred between two group was compared. Results: Total effective rate in research group was higher than that the control group, and the difference was statistically significant (P<0.05). After treatment 2 months, 4 months, menstrual quantity, menstrual pain score, endometrial thickness, uterine volume, in both group was decreased, the research group was lower than the control group(P<0.05).serum levels of NGF, sCD147, VEGF in both group were decreased, the research group was lower than the control group, and the difference was statistically significant (P<0.05). The adverse reactions between the two groups was no difference (P>0.05). Conclusion: Manyuela combined with low-dose mifepristone in the treatment of adenomyosis has a definite effect. It can effectively improve the clinical symptoms and reduce the levels of serum NGF, Scd147 and VEGF. It can be used as an optimal treatment for adenomyosis.

Key words： Adenomyosis Mirena Low-dose mifepristone Neurogrowth factor Vascular endothelial growth factor Soluble CD147

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xiaohong
	et al

Cite this article:

WU Xiaohong,et al. Clinical Efficacy of Menorrine combined with Small Dose Mifepristone in treatment of Adenomyosis Patients and its Influences on Nerve Growth Factor Soluble CD147 Vascular Endothelial Growth Factor[J]. HeBei Med, 2019, 25(1): 50-53.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.01.013 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I1/50